Sensus Healthcare (NASDAQ:SRTS) Director Purchases $31,939.32 in Stock

Sensus Healthcare, Inc. (NASDAQ:SRTS) Director Eric Sachetta bought 9,708 shares of the stock in a transaction dated Wednesday, August 26th. The shares were purchased at an average cost of $3.29 per share, for a total transaction of $31,939.32. Following the completion of the purchase, the director owned 219,018 shares in the company, valued at approximately $720,569.22. This represents a 4.64% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Eric Sachetta also recently made the following trade(s):

• On Thursday, August 27th, Eric Sachetta bought 10,925 shares of Sensus Healthcare stock. The shares were purchased at an average cost of $3.18 per share, with a total value of $34,741.50.
• On Monday, August 24th, Eric Sachetta purchased 34,697 shares of Sensus Healthcare stock. The stock was acquired at an average cost of $3.25 per share, for a total transaction of $112,765.25.

Sensus Healthcare Stock Performance

Shares of SRTS opened at $3.52 on Monday. The firm has a market capitalization of $57.94 million, a P/E ratio of -3.74 and a beta of 1.10. The firm has a 50-day moving average price of $3.05 and a 200 day moving average price of $3.51. Sensus Healthcare, Inc. has a 12-month low of $2.66 and a 12-month high of $5.49.

Sensus Healthcare (NASDAQ:SRTS) last posted its earnings results on Thursday, August 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.41). The business had revenue of $2.29 million for the quarter, compared to analyst estimates of $4.60 million. Sensus Healthcare had a negative return on equity of 21.57% and a negative net margin of 88.45%.

Wall Street Analyst Weigh In

Several research analysts have recently commented on SRTS shares. Weiss Ratings lowered shares of Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a research note on Tuesday, August 18th. Lake Street Capital cut their price objective on shares of Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Citigroup restated a “buy” rating on shares of Sensus Healthcare in a research note on Friday, May 8th. Wall Street Zen cut shares of Sensus Healthcare from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Finally, Alliance Global Partners reiterated a “buy” rating on shares of Sensus Healthcare in a research report on Monday, August 17th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $5.83.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. State Street Corp grew its holdings in Sensus Healthcare by 5.2% during the 4th quarter. State Street Corp now owns 69,252 shares of the company’s stock worth $276,000 after acquiring an additional 3,400 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Sensus Healthcare by 2.5% during the second quarter. Geode Capital Management LLC now owns 153,917 shares of the company’s stock worth $730,000 after acquiring an additional 3,766 shares during the last quarter. Sachetta LLC increased its position in Sensus Healthcare by 6.8% in the 4th quarter. Sachetta LLC now owns 148,508 shares of the company’s stock valued at $591,000 after acquiring an additional 9,500 shares during the period. EP Wealth Advisors LLC acquired a new position in shares of Sensus Healthcare during the second quarter valued at $49,000. Finally, XTX Topco Ltd bought a new stake in shares of Sensus Healthcare during the 4th quarter worth about $77,000. Institutional investors and hedge funds own 25.30% of the company’s stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.